Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefits in a variety of cancers. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified, all of them possibly being of high interest in immunotherapy research.
B7-H3 [CD276] has a co-inhibitory function on T cells. Its expression on either tumour cells or diffuse tumour vasculature is significantly associated with an increased risk of death and bad outcome. Targeting B7-H3 not only enhances anti-tumour immunity but also inhibits tumour angiogenesis.
B7-H4 plays a significant role in the “immune escape” of tumours and is a potential therapeutic target for the treatment of cancer. It plays an important role in the T cell-mediated immune response as a negative regulator. The ligation of B7-H4 to unidentified receptors results in the inhibition of TCR-mediated T cell proliferation, cell-cycle progression and IL-2 production.
VISTA [V-domain immunoglobulin suppressor of T cell Activation; B7-H5] is type I Ig membrane protein homologous to PD-L1. VISTA is mainly expressed on hematopoietic tissues (spleen, thymus and bone marrow) and on myeloid cells. VISTA is a new negative checkpoint regulator that potently suppresses T cell activation. It delivers a co-inhibitory impact on T cell response. Recent publications have reported that a recombinant VISTA protein needs to be multimerized to be active as a soluble ligand. The protein VISTA (mouse):COMP (mouse) (with the extracellular domain of mouse VISTA fused to the pentamerisation domain from the cartilage oligomeric matrix protein (COMP), but not VISTA-Fc, has been shown to function as an immunosuppressive agonist in vivo inhibiting the proliferation of CD4+ T cells. Additionally, a new function of the protein P-selectin glycoprotein ligand-1 (PSGL-1) as a new receptor for the immune checkpoint VISTA has been shown. Multimer VISTA binds PSGL-1 expressed on leukocytes at acidic pH, but not at the physiological pH 7. VISTA – PSGL-1 interaction shows that immune response can be regulated by acidic environments found in tumours.
B7-H6 (also known as NCR3LG1) is a ligand for NK cell activating receptor NKp30. It is expressed on tumour cells but can also be induced by inflammatory stress in healthy cells. B7-H6 has been validated as a potential target for antitumour immunotherapy strategies in tumour-bearing mice. The expression of B7-H6 is significantly correlated with post-operative prognosis in cancer patients and with distant metastasis status.
B7-H7 is widely expressed in human malignancies and its expression is associated with poor prognostic factors. Targeting B7-H7 not only benefits antitumour immunity but also inhibits tumour angiogenesis. For B7-H7, a T cell co-inhibitory role and a co-stimulatory role have been reported, most probably based on two counter receptors, one CD28H and the other unknown.
LIT: New B7 family checkpoints in human cancers: L. Ni & C. Dong; Mol. Cancer Ther. 16, 1203 (2017) • VISTA.COMP – an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses: A. Prodeus, et al.; JCI Insight 2, e94308 (2017)
NEW VISTA is an acidic pH-selective Ligand for PSGL-1
PSGL-1 (human):Fc (human) (rec.) (Prod. No. AG-40B-0190) binds to its ligand VISTA only at acidic pH.
Method: VISTA (human):COMP (mouse) (rec.) (His) (Prod. No. AG-40B-0183) or an unrelated protein Nampt (human) (His) (Prod. No. AG-40A-0031Y)(Control) is coated on an ELISA plate at 1μg/ml overnight at room temperature. PSGL-1 (human):Fc (human) (rec) (Prod. No. AG-40B-0190) is incubated (starting at 1000ng/ml with a twofold serial dilution) for one hour in mild acidic (pH 6.4) or neutral conditions (pH 7.4) and then detected using an anti-human Fc antibody (HRP).
NEW: B7-H3 (human) ELISA Kit – Biomarker for Immuno-Oncology Research
The B7-H3 (human) ELISA Kit (Prod. No. AG-45B-0025) is a sandwich ELISA for specific quantitative determination of soluble human B7-H3 (CD276) in serum, plasma and cell culture supernatants. Soluble human B7-H3 (CD276) is ectopically expressed in various cancers and its levels in serum of patients with cancer suggests it can be used as a noninvasive biomarker for diagnosis, prognosis and/or treatment response.
Biologically Active New B7 Family Proteins
See all Biologically Active New B7-H3 proteins here.
See all Biologically Active New B7-H4 proteins here.
See all Biologically Active New B7-H5 proteins from Chimerigen and AdipoGen Life Sciences.
See all Biologically Active New B7-H6 proteins here.
Originally posted on adipogen.com/new-b7-family-immune-checkpoint-proteins/
Caltag Medsystems is the distributor of Adipogen products in the UK and Ireland. If you have any questions about these products, please contact us.